Literature DB >> 2000222

Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells.

M Takahashi1, Y Buma, M Taniguchi.   

Abstract

Monoclonal and/or polyclonal antibodies were generated against the products synthesized from two portions of the ret proto-oncogene (c-ret) cDNA expressed in Escherichia coli. These antibodies were reactive in immunoblotting with 150 kd and 170 kd proteins in cell lysates from three human neuroblastoma cell lines expressing the ret proto-oncogene. When the neuroblastoma cells were treated with tunicamycin, a protein with an apparent molecular weight of 120 kd, which is consistent with that of the c-ret protein predicted from the cDNA sequence, appeared on immunoblots. These results indicated that the 150 kd and 170 kd proteins in neuroblastoma cells are produced from a single polypeptide of 120 kd by posttranslational glycosylation. Furthermore, the antibodies detected a unique 190 kd protein as well as 150 kd protein in a cell lysate from THP-1 human monocytic leukemia cell line, suggesting that glycosylated forms of the c-ret protein are different between neuroblastoma and leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2000222

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Role for GDNF in biochemical and behavioral adaptations to drugs of abuse.

Authors:  C J Messer; A J Eisch; W A Carlezon; K Whisler; L Shen; D H Wolf; H Westphal; F Collins; D S Russell; E J Nestler
Journal:  Neuron       Date:  2000-04       Impact factor: 17.173

2.  RFP is a DNA binding protein associated with the nuclear matrix.

Authors:  T Isomura; K Tamiya-Koizumi; M Suzuki; S Yoshida; M Taniguchi; M Matsuyama; T Ishigaki; S Sakuma; M Takahashi
Journal:  Nucleic Acids Res       Date:  1992-10-25       Impact factor: 16.971

3.  Src-dependent autophagic degradation of Ret in FAK-signalling-defective cancer cells.

Authors:  Emma Sandilands; Bryan Serrels; Simon Wilkinson; Margaret C Frame
Journal:  EMBO Rep       Date:  2012-06-26       Impact factor: 8.807

4.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 5.  [Molecular biology, basic research and diagnosis of Hirschsprung's disease].

Authors:  G Martucciello; O Luinetti; P Romano; U Magrini
Journal:  Pathologe       Date:  2007-03       Impact factor: 1.011

6.  Seventeen-year-long follow-up of a family affected by type 2A multiple endocrine neoplasia (MEN 2A).

Authors:  A Libroia; U Verga; G Vecchi; F Banfi; F Zurleni; L Quadro; C Scurini; O Fattoruso; V Colantuoni
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

Review 7.  Hirschsprung's disease as a neurochristopathy.

Authors:  G Martucciello
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

8.  No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.

Authors:  R M Hofstra; N C Cheng; C Hansen; R P Stulp; T Stelwagen; N Clausen; N Tommerup; H Caron; A Westerveld; R Versteeg; C H Buys
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

9.  Acidification of the Golgi apparatus is indispensable for maturation but not for cell surface delivery of Ret.

Authors:  Yoko Hirata; Norihiro Shimokawa; Kentaro Oh-hashi; Zu-Xi Yu; Kazutoshi Kiuchi
Journal:  J Neurochem       Date:  2010-09-28       Impact factor: 5.372

10.  Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.

Authors:  N Asai; T Iwashita; M Matsuyama; M Takahashi
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.